Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
de Luis
D A
DA
Aller
R
R
Cuellar
L
L
Terroba
C
C
Ovalle
H
H
Izaola
O
O
Romero
E
E
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*
D001786:Blood Glucose; D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; D007336:Insulin, Isophane; C072379:repaglinide